泽布替尼联合利妥昔单抗和来那度胺治疗初治弥漫性大B细胞淋巴瘤的2期研究
这项2期试验评估泽布替尼联合利妥昔单抗和来那度胺(ZR2)方案在≥75岁初治弥漫性大B细胞淋巴瘤(DLBCL)患者中的疗效与安全性。40例患者入组,诱导治疗结束时完全缓解率为65.0%(95%CI 48.3-78.9),2年无进展生存率和总生存率分别为67.1%和82.4%。ZR2疗效更多依赖肿瘤微环境而非遗传学改变,并与I类和II类人类白细胞抗原上调及cDC1数量和功能增加相关。
要点
- ≥75岁初治DLBCL患者接受ZR2方案,诱导结束时完全缓解率65.0%(95%CI 48.3-78.9)。
- 2年无进展生存率67.1%(95%CI 50.1-79.4),2年总生存率82.4%(95%CI 66.5-91.2)。
- 最常见3-4级血液学不良事件为中性粒细胞减少(14例[35.0%]),未观察到房颤事件。
核心结论
- ZR2方案在≥75岁初治DLBCL患者中显示出疗效,其疗效更多依赖肿瘤微环境改变而非遗传学改变。
- 瘤内CD8+ T细胞预存扩增和治疗诱导的T细胞受体克隆性 repertoire 与更好的临床结局相关。
- 这些发现支持基于机制的靶向治疗侵袭性淋巴瘤的范式转变。
研究设计与样本
- 2期试验,纳入40例≥75岁初治弥漫性大B细胞淋巴瘤患者,接受泽布替尼联合利妥昔单抗和来那度胺(ZR2)治疗。
- 主要终点为诱导治疗结束时的完全缓解率。
- 试验注册号NCT04460248。
主要发现
- 诱导治疗结束时完全缓解率为65.0%(95%CI 48.3-78.9)。
- 2年无进展生存率为67.1%(95%CI 50.1-79.4),2年总生存率为82.4%(95%CI 66.5-91.2)。
- 最常见3-4级血液学不良事件为中性粒细胞减少(14例[35.0%])。
- 最常见3-4级非血液学不良事件为丙氨酸转氨酶升高(5例[12.5%])、天冬氨酸转氨酶升高(5例[12.5%])和肺部感染(5例[12.5%])。
- 未观察到房颤事件;ZR2疗效与I类和II类人类白细胞抗原上调及cDC1数量和功能增加相关。
关键数值与推荐
- 完全缓解率65.0%(95%CI 48.3-78.9),对象为40例≥75岁初治DLBCL患者诱导治疗结束时。
- 2年无进展生存率67.1%(95%CI 50.1-79.4),2年总生存率82.4%(95%CI 66.5-91.2)。
- 3-4级中性粒细胞减少14例(35.0%)。
- 3-4级丙氨酸转氨酶升高5例(12.5%),天冬氨酸转氨酶升高5例(12.5%),肺部感染5例(12.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older patients with diffuse large B-cell lymphoma (DLBCL) present unfavorable genetic and microenvironmental alterations. In this phase 2 trial, we assessed the efficacy and safety of zanubrutinib in combination with rituximab and lenalidomide (ZR2) in patients with de novo DLBCL aged ≥75 years. Forty patients were enrolled, and the primary end point was the complete response rate, which was 65.0% (95% confidence interval [CI], 48.3-78.9) at the end of induction treatment. The 2-year progression-free and overall survival rates were 67.1% (95% CI, 50.1-79.4) and 82.4% (95% CI, 66.5-91.2). The most common grades 3 and 4 hematologic adverse event (AE) was neutropenia (n = 14 [35.0%]). The most common grades 3 and 4 nonhematologic AEs were increased alanine transaminase (n = 5 [12.5%]) and aspartate transaminase levels (n = 5; 12.5%), and pulmonary infection (n = 5 [12.5%]). No events of atrial fibrillation were observed. Importantly, the efficacy of ZR2 was more dependent on tumor microenvironmental than genetic alterations, and was associated with upregulation of class I and II human leukocyte antigen and increased number and function of conventional type 1 dendritic cells. Preexisting expansion of intratumoral CD8+ T cells and treatment-induced clonal T-cell receptor (TCR) repertoire contributed to better clinical outcome. TCR sequencing of the peripheral blood mononuclear cell samples from patients with durable remission detected the expanded T-cell clones 3 years after treatment. These findings thus improve the understanding of the effect of T-cell immunological memory on ZR2-based immunotherapy, and support a paradigm shift toward mechanism-based targeted therapy of aggressive lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT04460248.
引用
- Xu PP, Zhu Y, Shi ZY, et al. A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma. Blood. 2025. PMID: 40829156. doi:10.1182/blood.2025028649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。